Literature DB >> 29288201

Murine Red Blood Cells Lack Ligands for B Cell Siglecs, Allowing Strong Activation by Erythrocyte Surface Antigens.

Fernando Spiller1,2, Corwin M Nycholat1,2, Chika Kikuchi1,2, James C Paulson3,2, Matthew S Macauley4.   

Abstract

CD22 and sialic acid-binding Ig-like lectin (Siglec)-G are members of the Siglec family of inhibitory coreceptors expressed on B cells that participate in enforcement of peripheral B cell tolerance. We have shown previously that when a BCR engages its cognate Ag on a cell surface that also expresses Siglec ligands, B cell Siglecs are recruited to the immunological synapse, resulting in suppression of BCR signaling and B cell apoptosis. Because all cells display sialic acids, and CD22 and Siglec-G have distinct, yet overlapping, specificities for sialic acid-containing glycan ligands, any cell could, in principle, invoke this tolerogenic mechanism for cell surface Ags. However, we show in this article that C57BL/6J mouse RBCs are essentially devoid of CD22 and Siglec-G ligands. As a consequence, RBCs that display a cell surface Ag, membrane-bound hen egg lysozyme, strongly activate Ag-specific B cells. We reasoned that de novo introduction of CD22 ligands in RBCs should abolish B cell activation toward its cognate Ag on the surface of RBCs. Accordingly, we used a glyco-engineering approach wherein synthetic CD22 ligands linked to lipids are inserted into the membrane of RBCs. Indeed, insertion of CD22 ligands into the RBC cell surface strongly inhibited B cell activation, cytokine secretion, and proliferation. These results demonstrate that the lack of Siglec ligands on the surface of murine RBCs permits B cell responses to erythrocyte Ags and show that Siglec-mediated B cell tolerance is restricted to cell types that express glycan ligands for the B cell Siglecs.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29288201      PMCID: PMC5780208          DOI: 10.4049/jimmunol.1701257

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs.

Authors:  Nicole H Smith; Eldad A Hod; Steven L Spitalnik; James C Zimring; Jeanne E Hendrickson
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

Review 2.  The early history of B cells.

Authors:  Max D Cooper
Journal:  Nat Rev Immunol       Date:  2015-02-06       Impact factor: 53.106

3.  Erythrocyte sialoglycoproteins engage Siglec-9 on neutrophils to suppress activation.

Authors:  Anel Lizcano; Ismael Secundino; Simon Döhrmann; Ross Corriden; Cristina Rohena; Sandra Diaz; Pradipta Ghosh; Lingquan Deng; Victor Nizet; Ajit Varki
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

4.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

Authors:  Stephan Kontos; Iraklis C Kourtis; Karen Y Dane; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

5.  Siglecs induce tolerance to cell surface antigens by BIM-dependent deletion of the antigen-reactive B cells.

Authors:  Matthew S Macauley; James C Paulson
Journal:  J Immunol       Date:  2014-09-24       Impact factor: 5.422

6.  Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.

Authors:  Ross M Fasano; Garrett S Booth; Megan Miles; Liping Du; Tatsuki Koyama; Emily Riehm Meier; Naomi L C Luban
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

7.  Identification of 9-O-acetyl-N-acetylneuraminic acid on the surface of BALB/c mouse erythrocytes.

Authors:  G Reuter; J F Vliegenthart; M Wember; R Schauer; R J Howard
Journal:  Biochem Biophys Res Commun       Date:  1980-05-30       Impact factor: 3.575

8.  In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

Authors:  Weihsu C Chen; Gladys C Completo; Darren S Sigal; Paul R Crocker; Alan Saven; James C Paulson
Journal:  Blood       Date:  2010-02-24       Impact factor: 22.113

9.  Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169.

Authors:  Weihsu C Chen; Norihito Kawasaki; Corwin M Nycholat; Shoufa Han; Julie Pilotte; Paul R Crocker; James C Paulson
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

10.  Natural ligands of the B cell adhesion molecule CD22 beta can be masked by 9-O-acetylation of sialic acids.

Authors:  E R Sjoberg; L D Powell; A Klein; A Varki
Journal:  J Cell Biol       Date:  1994-07       Impact factor: 10.539

View more
  5 in total

Review 1.  Structure and function of the immune system in the spleen.

Authors:  Steven M Lewis; Adam Williams; Stephanie C Eisenbarth
Journal:  Sci Immunol       Date:  2019-03-01

2.  The red blood cell as a novel regulator of human B-cell activation.

Authors:  Charlotte S Lennon; Huan Cao; Andrew M Hall; Mark A Vickers; Robert N Barker
Journal:  Immunology       Date:  2021-05-06       Impact factor: 7.215

Review 3.  B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.

Authors:  Sarah J Meyer; Alexandra T Linder; Carolin Brandl; Lars Nitschke
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

4.  CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.

Authors:  Naoko Matsubara; Akihiro Imamura; Tatsuya Yonemizu; Chizuru Akatsu; Hongrui Yang; Akiharu Ueki; Natsuki Watanabe; Hajjaj Abdu-Allah; Nobutaka Numoto; Hiromu Takematsu; Shinobu Kitazume; Thomas F Tedder; Jamey D Marth; Nobutoshi Ito; Hiromune Ando; Hideharu Ishida; Makoto Kiso; Takeshi Tsubata
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

5.  Systemic ST6Gal-1 Is a Pro-survival Factor for Murine Transitional B Cells.

Authors:  Eric E Irons; Joseph T Y Lau
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.